EP2114449A4 - Herpes simplex virus combined subunit vaccines and methods of use thereof - Google Patents

Herpes simplex virus combined subunit vaccines and methods of use thereof

Info

Publication number: EP2114449A4
Authority: EP; European Patent Office
Prior art keywords: methods; herpes simplex; simplex virus; subunit vaccines; virus combined
Prior art date: 2006-12-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP20070863257

Other languages

German (de)

French (fr)

Other versions

EP2114449B1 (en

EP2114449A1 (en

Inventor

Harvey Friedman

Sita Awasthi

John Lubinski

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Pennsylvania Penn

Original Assignee

University of Pennsylvania Penn

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-28

Filing date

2007-12-27

Publication date

2010-03-17

2007-12-27 Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn

2007-12-27 Priority to EP20130151069 priority Critical patent/EP2591800A1/en

2007-12-27 Priority to EP20120172925 priority patent/EP2502634A1/en

2007-12-27 Priority to EP12172930.5A priority patent/EP2526966B1/en

2009-11-11 Publication of EP2114449A1 publication Critical patent/EP2114449A1/en

2010-03-17 Publication of EP2114449A4 publication Critical patent/EP2114449A4/en

2016-02-17 Application granted granted Critical

2016-02-17 Publication of EP2114449B1 publication Critical patent/EP2114449B1/en

Status Active legal-status Critical Current

2027-12-27 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16661—Methods of inactivation or attenuation
- C12N2710/16662—Methods of inactivation or attenuation by genetic engineering

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Mycology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Tropical Medicine & Parasitology (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
AIDS & HIV (AREA)
Endocrinology (AREA)

EP07863257.7A 2006-12-28 2007-12-27 Herpes simplex virus combined subunit vaccines and methods of use thereof Active EP2114449B1 (en)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
EP20130151069 EP2591800A1 (en)	2006-12-28	2007-12-27	Herpes simplex virus combined subunit vaccines and methods of use thereof
EP20120172925 EP2502634A1 (en)	2006-12-28	2007-12-27	Herpes simplex virus combined subunit vaccines and methods of use thereof
EP12172930.5A EP2526966B1 (en)	2006-12-28	2007-12-27	Herpes simplex virus combined subunit vaccines and methods of use thereof

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US87737806P	2006-12-28	2006-12-28
US92910507P	2007-06-13	2007-06-13
US99672407P	2007-12-03	2007-12-03
PCT/US2007/026352 WO2008085486A1 (en)	2006-12-28	2007-12-27	Herpes simplex virus combined subunit vaccines and methods of use thereof

Related Child Applications (5)

Application Number	Title	Priority Date	Filing Date
EP12172930.5A Division EP2526966B1 (en)	2006-12-28	2007-12-27	Herpes simplex virus combined subunit vaccines and methods of use thereof
EP12172930.5A Division-Into EP2526966B1 (en)	2006-12-28	2007-12-27	Herpes simplex virus combined subunit vaccines and methods of use thereof
EP20130151069 Division-Into EP2591800A1 (en)	2006-12-28	2007-12-27	Herpes simplex virus combined subunit vaccines and methods of use thereof
EP20120172925 Division EP2502634A1 (en)	2006-12-28	2007-12-27	Herpes simplex virus combined subunit vaccines and methods of use thereof
EP20120172925 Division-Into EP2502634A1 (en)	2006-12-28	2007-12-27	Herpes simplex virus combined subunit vaccines and methods of use thereof

Publications (3)

Publication Number	Publication Date
EP2114449A1 EP2114449A1 (en)	2009-11-11
EP2114449A4 true EP2114449A4 (en)	2010-03-17
EP2114449B1 EP2114449B1 (en)	2016-02-17

Family

ID=39608954

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
EP07863257.7A Active EP2114449B1 (en)	2006-12-28	2007-12-27	Herpes simplex virus combined subunit vaccines and methods of use thereof
EP12172930.5A Active EP2526966B1 (en)	2006-12-28	2007-12-27	Herpes simplex virus combined subunit vaccines and methods of use thereof
EP20130151069 Withdrawn EP2591800A1 (en)	2006-12-28	2007-12-27	Herpes simplex virus combined subunit vaccines and methods of use thereof
EP20120172925 Withdrawn EP2502634A1 (en)	2006-12-28	2007-12-27	Herpes simplex virus combined subunit vaccines and methods of use thereof

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
EP12172930.5A Active EP2526966B1 (en)	2006-12-28	2007-12-27	Herpes simplex virus combined subunit vaccines and methods of use thereof
EP20130151069 Withdrawn EP2591800A1 (en)	2006-12-28	2007-12-27	Herpes simplex virus combined subunit vaccines and methods of use thereof
EP20120172925 Withdrawn EP2502634A1 (en)	2006-12-28	2007-12-27	Herpes simplex virus combined subunit vaccines and methods of use thereof

Country Status (7)

Country	Link
US (1)	US9284355B2 (en)
EP (4)	EP2114449B1 (en)
JP (1)	JP6144448B2 (en)
CN (1)	CN101616688B (en)
AU (1)	AU2007342345B9 (en)
CA (1)	CA2674051C (en)
WO (1)	WO2008085486A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US7585847B2 (en) *	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
CN101583381B (en)	2006-09-08	2014-05-07	宾夕法尼亚大学董事会	HSV-1 and HSV-2 vaccines and methods of use thereof
US8865185B2 (en)	2006-09-08	2014-10-21	The Trustees Of The University Of Pennsylvania	Methods of use for HSV-1 and HSV-2 vaccines
US10478490B2 (en)	2006-12-28	2019-11-19	The Trustees Of The University Of Pennsylvania	Herpes simplex virus combined subunit vaccines and methods of use thereof
EP2114449B1 (en)	2006-12-28	2016-02-17	The Trustees of the University of Pennsylvania	Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2010135747A1 (en)	2009-05-22	2010-11-25	Genocea Biosciences Inc.	Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
AU2011336894B2 (en)	2010-11-24	2016-11-17	Genocea Biosciences, Inc.	Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
JP6199878B2 (en)	2011-11-23	2017-09-20	ジェノセアバイオサイエンシーズ，インコーポレイテッド	Nucleic acid vaccine against herpes simplex virus type 2: Compositions and methods for inducing an immune response
CN103740736B (en) *	2013-12-31	2016-08-17	李越希	The HSV2 virus gE glucoprotein extracellular region gene fragment of chemosynthesis and expression, application
CN103740735B (en) *	2013-12-31	2016-04-06	李越希	Chemosynthesis HSV2 virus gC glucoprotein extracellular region gene fragment and expression, application
US10918712B2 (en)	2014-03-03	2021-02-16	Albert Einstein College Of Medicine	Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
EP3113801B1 (en)	2014-03-03	2020-10-07	Albert Einstein College of Medicine	Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
CN104940923B (en) *	2015-06-26	2017-10-10	东南大学	A kind of herpes simplex keratitis vaccine and preparation method thereof
JP2019537555A (en)	2016-09-28	2019-12-26	ジェノセアバイオサイエンシーズ，インコーポレイテッド	Methods and compositions for treating herpes
WO2018170256A1 (en)	2017-03-15	2018-09-20	Modernatx, Inc.	Herpes simplex virus vaccine
MA49421A (en)	2017-06-15	2020-04-22	Modernatx Inc	RNA FORMULATIONS
EP3677592B1 (en) *	2017-08-30	2024-07-17	KM Biologics Co., Ltd.	Modified hsv gd protein and vaccine containing same
US11744801B2 (en)	2017-08-31	2023-09-05	Modernatx, Inc.	Methods of making lipid nanoparticles
US12090235B2 (en)	2018-09-20	2024-09-17	Modernatx, Inc.	Preparation of lipid nanoparticles and methods of administration thereof
US20210340223A1 (en) *	2018-10-11	2021-11-04	Trustees Of Dartmouth College	Compositions and methods for preventing or ameliorating neonatal hsv infection
US12070495B2 (en)	2019-03-15	2024-08-27	Modernatx, Inc.	HIV RNA vaccines
BR112022000710A2 (en) *	2019-07-21	2022-03-22	Glaxosmithkline Biologicals Sa	Therapeutic viral vaccine
US20230073321A1 (en) *	2019-12-13	2023-03-09	Grand Theravac Life Science (Nanjing) Co., Ltd.	Pharmaceutical composition and use thereof
US20240091380A1 (en)	2021-02-01	2024-03-21	Regenxbio Inc.	Gene therapy for neuronal ceroid lipofuscinoses
WO2024163918A1 (en)	2023-02-02	2024-08-08	University Of Houston System	Mrna vaccine for herpes simplex virus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001008701A2 (en) *	1999-08-03	2001-02-08	International Centre For Genetic Engineering And Biotechnology	Invasive bacteria based viral vaccines
WO2002087614A2 (en) *	2001-04-27	2002-11-07	Glaxosmithkline Biologicals S.A.	Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4762708A (en)	1982-02-18	1988-08-09	University Patents, Inc.	Materials and methods for herpes simplex virus vaccination
US4709011A (en)	1982-02-18	1987-11-24	University Patents, Inc.	Materials and methods for herpes simplex virus vaccination
US7264817B1 (en)	1983-08-30	2007-09-04	Genentech, Inc.	Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
NZ209308A (en) *	1983-08-30	1991-08-27	Genentech Inc	Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5171568A (en)	1984-04-06	1992-12-15	Chiron Corporation	Recombinant herpes simplex gb-gd vaccine
US5612041A (en) *	1984-07-17	1997-03-18	Chiron Corporation	Recombinant herpes simplex gD vaccine
US5149529A (en) *	1988-04-08	1992-09-22	Board Of Trustees Of Leland Chiron Corporation	Compositions and treatment for herpes simplex
GB8918616D0 (en)	1989-08-15	1989-09-27	Univ Glasgow	Herpes simplex virus type 1 mutant
US6193984B1 (en)	1992-02-03	2001-02-27	Cedars-Sinai Medical Center	Pharmaceutical composition of herpes simplex virus typ-1 (HSV-1) glycoproteins
US5955088A (en) *	1992-02-03	1999-09-21	Cedars-Sinai Medical Center	Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5754171A (en) *	1992-10-21	1998-05-19	Photonics Systems, Inc.	Display device having integrated circuit chips thereon
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US6156319A (en) *	1994-07-25	2000-12-05	The Trustees Of The University Of Pennsylvania	Soluble herpesvirus glycoprotein complex vaccine
GB9415319D0 (en)	1994-07-29	1994-09-21	Medical Res Council	HSV viral vector
EP0811057B1 (en)	1995-02-21	2006-04-26	Cantab Pharmaceuticals Research Limited	Viral preparations, vectors, immunogens, and vaccines
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
IL137998A0 (en) *	1998-03-09	2001-10-31	Smithkline Beecham Biolog	Combined vaccine compositions
IL131212A0 (en)	1999-08-03	2001-01-28	Yissum Res Dev Co	Recombinant virus and live-virus vaccines
US6821519B2 (en)	2000-06-29	2004-11-23	Corixa Corporation	Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
ES2539941T3 (en)	2001-05-09	2015-07-07	Takara Bio, Inc.	Composition and method to treat cancer using herpes virus
US20030215463A1 (en)	2002-03-22	2003-11-20	David Knipe	Means of inducing durable immune responses
US20040197347A1 (en) *	2002-09-23	2004-10-07	Board Of Regents, The University Of Texas System	Methods for vaccine identification and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the herpesvirus family
EP1415665A3 (en)	2002-11-01	2004-06-30	ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V.	BHV5 mutants
US7592169B2 (en)	2003-04-25	2009-09-22	Medimmune, Llc	Methods and compositions for treatment and prevention of HSV-2 infections and conditions
US8865185B2 (en)	2006-09-08	2014-10-21	The Trustees Of The University Of Pennsylvania	Methods of use for HSV-1 and HSV-2 vaccines
CN101583381B (en)	2006-09-08	2014-05-07	宾夕法尼亚大学董事会	HSV-1 and HSV-2 vaccines and methods of use thereof
US20130028925A1 (en)	2006-12-28	2013-01-31	Harvey Friedman	Herpes simplex virus combined subunit vaccines and methods of use thereof
EP2114449B1 (en)	2006-12-28	2016-02-17	The Trustees of the University of Pennsylvania	Herpes simplex virus combined subunit vaccines and methods of use thereof
US8057804B2 (en)	2006-12-28	2011-11-15	The Trustees Of The University Of Pennsylvania	Herpes simplex virus combined subunit vaccines and methods of use thereof
US10478490B2 (en)	2006-12-28	2019-11-19	The Trustees Of The University Of Pennsylvania	Herpes simplex virus combined subunit vaccines and methods of use thereof

2007
- 2007-12-27 EP EP07863257.7A patent/EP2114449B1/en active Active
- 2007-12-27 US US12/005,407 patent/US9284355B2/en active Active
- 2007-12-27 EP EP12172930.5A patent/EP2526966B1/en active Active
- 2007-12-27 AU AU2007342345A patent/AU2007342345B9/en active Active
- 2007-12-27 WO PCT/US2007/026352 patent/WO2008085486A1/en active Application Filing
- 2007-12-27 CN CN2007800518606A patent/CN101616688B/en active Active
- 2007-12-27 EP EP20130151069 patent/EP2591800A1/en not_active Withdrawn
- 2007-12-27 JP JP2009544088A patent/JP6144448B2/en active Active
- 2007-12-27 CA CA2674051A patent/CA2674051C/en active Active
- 2007-12-27 EP EP20120172925 patent/EP2502634A1/en not_active Withdrawn

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001008701A2 (en) *	1999-08-03	2001-02-08	International Centre For Genetic Engineering And Biotechnology	Invasive bacteria based viral vaccines
WO2002087614A2 (en) *	2001-04-27	2002-11-07	Glaxosmithkline Biologicals S.A.	Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHANG ET AL: "Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 23, no. 38, 7 September 2005 (2005-09-07), pages 4658 - 4665, XP005021728, ISSN: 0264-410X *
MANSERVIGI R ET AL: "Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 23, no. 7, 4 January 2005 (2005-01-04), pages 865 - 872, XP004685021, ISSN: 0264-410X *
MUKHLIS F A ET AL: "Characterization and immunogenicity of HSV-1 antigens obtained following zwitterionic detergent treatment", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 4, no. 3, 1 September 1986 (1986-09-01), pages 191 - 196, XP023710297, ISSN: 0264-410X, [retrieved on 19860901] *
NASS PETRA H ET AL: "Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins", JOURNAL OF INFECTIOUS DISEASES, vol. 178, no. 3, September 1998 (1998-09-01), pages 611 - 617, XP009128848, ISSN: 0022-1899 *
OSORIO YANIRA ET AL: "Improved protection from primary ocular HSV-1 infection and establishment of latency using multigenic DNA vaccines.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE FEB 2004, vol. 45, no. 2, February 2004 (2004-02-01), pages 506 - 514, XP002566514, ISSN: 0146-0404 *
See also references of WO2008085486A1 *

Also Published As

Publication number	Publication date
WO2008085486A1 (en)	2008-07-17
EP2526966A3 (en)	2013-03-13
EP2526966A2 (en)	2012-11-28
CN101616688B (en)	2013-12-11
US9284355B2 (en)	2016-03-15
EP2591800A1 (en)	2013-05-15
AU2007342345B2 (en)	2013-09-05
JP6144448B2 (en)	2017-06-07
EP2526966B1 (en)	2016-03-23
CA2674051A1 (en)	2008-07-17
EP2502634A1 (en)	2012-09-26
US20090098162A1 (en)	2009-04-16
AU2007342345A1 (en)	2008-07-17
EP2114449B1 (en)	2016-02-17
AU2007342345B9 (en)	2013-09-12
JP2010514767A (en)	2010-05-06
CN101616688A (en)	2009-12-30
CA2674051C (en)	2017-10-31
EP2114449A1 (en)	2009-11-11

Publication	Publication Date	Title
EP2114449A4 (en)	2010-03-17	Herpes simplex virus combined subunit vaccines and methods of use thereof
GB2446721B (en)	2009-03-25	Herpes simplex viruses and methods of viral replication
IL206156A0 (en)	2010-12-30	Antibodies against influenza virus and methods of use thereof
IL216508A (en)	2016-08-31	Vaccines against herpes simplex virus type 1 and/or type 2 and compositions and uses thereof
EP1766094A4 (en)	2009-11-25	Influenza virus vaccine composition and method of use
EP2021455A4 (en)	2014-01-01	Cytoblock preparation system and methods of use
ZA200808022B (en)	2009-09-30	Inhibitors of human immunodeficiency virus replication
ZA200710974B (en)	2008-10-29	Inactivated chimeric vaccines and related methods of use
EP1838291A4 (en)	2008-12-03	Pharmaceutical formulations and methods of use
EP1984405A4 (en)	2010-06-30	Influenza antigens, vaccine compositions, and related methods
IL176486A0 (en)	2006-10-05	Azabenzofuran substituted thioureas as inhibtitors of viral replication
EP2010210A4 (en)	2010-07-21	Vaccine for avian influenza and methods of use
IL193397A0 (en)	2011-08-01	Hpv antigens, vaccine compositions, and related methods
ZA200804688B (en)	2009-04-29	Purine derivatives and methods of use thereof
ZA200900203B (en)	2013-06-26	Adjuvants and methods of use
HRP20160573T1 (en)	2016-09-23	Herpes simplex virus vaccines
EP1982145A4 (en)	2012-10-24	Alignment correction system and methods of use thereof
EP2117588A4 (en)	2011-05-04	Viral vectors and methods of use
EP2379590A4 (en)	2013-03-20	Anti-herpes simplex virus antibodies and methods of use thereof
EP1778281A4 (en)	2010-01-20	Vaccination of skunks and/or mongooses against rabies
HK1112199A1 (en)	2008-08-29	Coccidial vaccine and methods of making and using same
EP1776140A4 (en)	2010-09-08	Methods of inhibiting viral replication
EP1735338A4 (en)	2008-04-16	Anthrax antigens and methods of use
GB0722040D0 (en)	2007-12-19	Sustained release methotrexate formulations and methods of use thereof
GB0609381D0 (en)	2006-06-21	Treatment using herpes simplex virus

Legal Events

Date	Code	Title	Description
2009-10-09	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2009-11-11	17P	Request for examination filed	Effective date: 20090728
2009-11-11	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
2010-03-17	A4	Supplementary search report drawn up and despatched	Effective date: 20100215
2010-04-07	DAX	Request for extension of the european patent (deleted)
2010-07-14	17Q	First examination report despatched	Effective date: 20100611
2014-12-24	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/245 20060101AFI20141118BHEP Ipc: C12N 7/00 20060101ALI20141118BHEP Ipc: A61K 39/00 20060101ALI20141118BHEP Ipc: C07K 14/005 20060101ALI20141118BHEP
2015-02-18	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2015-03-18	INTG	Intention to grant announced	Effective date: 20150218
2015-07-24	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2015-08-02	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2015-08-05	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/00 20060101ALI20150626BHEP Ipc: C07K 14/005 20060101ALI20150626BHEP Ipc: A61K 39/245 20060101AFI20150626BHEP Ipc: C12N 7/00 20060101ALI20150626BHEP Ipc: A61K 39/12 20060101ALI20150626BHEP
2015-09-02	INTG	Intention to grant announced	Effective date: 20150803
2015-12-04	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2016-01-15	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2016-02-17	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
2016-02-17	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2016-02-29	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2016-03-09	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2016-03-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 775321 Country of ref document: AT Kind code of ref document: T Effective date: 20160315
2016-03-31	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602007044925 Country of ref document: DE
2016-06-22	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20160217
2016-06-27	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2016-07-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 775321 Country of ref document: AT Kind code of ref document: T Effective date: 20160217
2016-07-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217
2016-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160617 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217
2016-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217
2016-11-11	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10
2016-11-18	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602007044925 Country of ref document: DE
2016-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217
2016-12-23	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2016-12-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2016-12-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217
2017-01-25	26N	No opposition filed	Effective date: 20161118
2017-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160517
2017-07-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2017-09-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217
2017-10-04	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2017-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161231 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161231 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161227
2017-11-13	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11
2017-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161227
2018-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20071227
2018-06-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217
2018-09-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161227
2023-06-28	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230524
2024-01-18	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20231102 Year of fee payment: 17
2024-01-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20231108 Year of fee payment: 17 Ref country code: DE Payment date: 20231031 Year of fee payment: 17